RemeGen Co., Ltd. Drug Pipeline

RemeGen Co., Ltd. maintains a substantial clinical development portfolio, with 33 active trials out of 66 total trials registered since 2008. The pipeline spans early- to late-stage development, encompassing 12 active Phase 1 trials, 21 in Phase 2, and 11 in Phase 3. RemeGen’s research is focused across five therapeutic areas, with a significant concentration in oncology, which accounts for approximately 85% of active programs (28 trials). Within oncology, the portfolio is further weighted toward solid tumors, particularly advanced solid tumors (7 active trials, including 1 in Phase 3), non-small cell lung cancer (5 active trials, including 1 in Phase 3), breast cancer (4 active trials), bladder cancer (3 active trials, including 1 in Phase 3), and gastric cancer (3 active trials, including 2 in Phase 3). Outside of oncology, the company also has active trials in immunology and metabolic diseases, with one active trial each. The relatively high number of Phase 3 trials in oncology suggests a potential for near-term clinical catalysts in this therapeutic area.